About ViroCarb

Our goal is for patients to receive safe treatment against viral infection, Virocarb candidate drug stops reproduction of known and potential new viruses.

ViroCarb is a science-driven biotech company focused on the development and commercialization of innovative drugs for viral infections with urgent unmet therapeutic needs. 

Our approach of blocking host cell’s processes needed for viral replication overcomes the limitations of current antiviral drug development, directed against viral-encoded targets, caused by extensive viral mutations that limit efficacy and promote drug resistance (e.g. DNA polymerase, reverse transcriptase, protease, and neuraminidase inhibitors).

Website: www.virocarb.com

Your Feedback

Your feedback is very important to CAIF and also our Startup Companies. Please let us know how we did. If you would like to know more information about the Startup Company, please leave us a feedback as well.